A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Fotheringham
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors S. Fotheringham1, H. Danielsen2, T. Hveem3, E. Domingo3, M. Pradhan3, R. Syvertsen3, I. Kostolomov3, J. Nesheim3, E. Johnstone3, M. Novelli3, I. Tomlinson3, R. Kerr3, D. Kerr3
  • 1Oxford Cancer Biomarkers Ltd, Oxford, UK, /
  • 2Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway, /
  • 3Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway, /


Validated prognostic biomarkers are required to facilitate therapeutic decisions in colorectal cancer (CRC). We report here the prognostic value of ploidy, digital tumour-stromal morphometric, and mutational analyses using material from 1074 patients with early stage CRC.